145 related articles for article (PubMed ID: 35752822)
21. Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.
Perez TY; Danzig MR; Ghandour RA; Badani KK; Benson MC; McKiernan JM
Urology; 2015 Jan; 85(1):85-9. PubMed ID: 25440819
[TBL] [Abstract][Full Text] [Related]
22. Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.
Kim SP; Karnes RJ; Gross CP; Meropol NJ; Van Houten H; Abouassaly R; Shah ND
Urology; 2016 Nov; 97():111-117. PubMed ID: 27527411
[TBL] [Abstract][Full Text] [Related]
23. Changes in the outcome of prostate biopsies after preventive task force recommendation against prostate-specific antigen screening.
Zakaria AS; Dragomir A; Brimo F; Kassouf W; Tanguay S; Aprikian A
BMC Urol; 2018 Aug; 18(1):69. PubMed ID: 30126402
[TBL] [Abstract][Full Text] [Related]
24. PSA Testing Use and Prostate Cancer Diagnostic Stage After the 2012 U.S. Preventive Services Task Force Guideline Changes.
Magnani CJ; Li K; Seto T; McDonald KM; Blayney DW; Brooks JD; Hernandez-Boussard T
J Natl Compr Canc Netw; 2019 Jul; 17(7):795-803. PubMed ID: 31319390
[TBL] [Abstract][Full Text] [Related]
25. The politics of prostate cancer screening.
Kaffenberger SD; Penson DF
Urol Clin North Am; 2014 May; 41(2):249-55. PubMed ID: 24725487
[TBL] [Abstract][Full Text] [Related]
26. Racial disparities in prostate cancer survival in a screened population: Reality versus artifact.
Kaur D; Ulloa-Pérez E; Gulati R; Etzioni R
Cancer; 2018 Apr; 124(8):1752-1759. PubMed ID: 29370459
[TBL] [Abstract][Full Text] [Related]
27. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
Drazer MW; Huo D; Eggener SE
J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
[TBL] [Abstract][Full Text] [Related]
28. Effect of the USPSTF Grade D Recommendation against Screening for Prostate Cancer on Incident Prostate Cancer Diagnoses in the United States.
Barocas DA; Mallin K; Graves AJ; Penson DF; Palis B; Winchester DP; Chang SS
J Urol; 2015 Dec; 194(6):1587-93. PubMed ID: 26087383
[TBL] [Abstract][Full Text] [Related]
29. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
Eapen RS; Herlemann A; Washington SL; Cooperberg MR
Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
[TBL] [Abstract][Full Text] [Related]
30. Effects of the 2012 and 2018 US preventive services task force prostate cancer screening guidelines on pathologic outcomes after prostatectomy.
Plambeck BD; Wang LL; Mcgirr S; Jiang J; Van Leeuwen BJ; Lagrange CA; Boyle SL
Prostate; 2022 Feb; 82(2):216-220. PubMed ID: 34807485
[TBL] [Abstract][Full Text] [Related]
31. Decline in Prostate Cancer Screening by Primary Care Physicians: An Analysis of Trends in the Use of Digital Rectal Examination and Prostate Specific Antigen Testing.
Shoag J; Halpern JA; Lee DJ; Mittal S; Ballman KV; Barbieri CE; Hu JC
J Urol; 2016 Oct; 196(4):1047-52. PubMed ID: 27060052
[TBL] [Abstract][Full Text] [Related]
32. Prostate Cancer Screening and the Associated Controversy.
Tabayoyong W; Abouassaly R
Surg Clin North Am; 2015 Oct; 95(5):1023-39. PubMed ID: 26315521
[TBL] [Abstract][Full Text] [Related]
33. Trends in Prostate Cancer Incidence Rates and Prevalence of Prostate Specific Antigen Screening by Socioeconomic Status and Regions in the United States, 2004 to 2013.
Houston KA; King J; Li J; Jemal A
J Urol; 2018 Mar; 199(3):676-682. PubMed ID: 28965781
[TBL] [Abstract][Full Text] [Related]
34. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
[TBL] [Abstract][Full Text] [Related]
35. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
36. Increasing aggressive prostate cancer.
Shah N; Ioffe V; Chang JC
Can J Urol; 2022 Dec; 29(6):11384-11390. PubMed ID: 36495581
[TBL] [Abstract][Full Text] [Related]
37. Long-term consequences of the USPSTF Grade D recommendation for prostate-specific antigen screening.
Joshi SS; Filson CP
Cancer; 2020 Feb; 126(4):694-696. PubMed ID: 31794066
[No Abstract] [Full Text] [Related]
38. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology.
Kang JJ; Reiter RE; Steinberg ML; King CR
Eur Urol Oncol; 2018 Oct; 1(5):378-385. PubMed ID: 31158076
[TBL] [Abstract][Full Text] [Related]
39. Does screening for prostate cancer improve cancer-specific mortality in Asian men? Real-world data in Yokosuka City 15 years after introducing PSA-based population screening.
Tabei T; Taguri M; Sakai N; Koh H; Yosida M; Fujikawa A; Nirei T; Tsutsumi S; Ito H; Furuhata S; Kawahara T; Miyoshi Y; Noguchi S; Uemura H; Kobayashi K
Prostate; 2020 Aug; 80(11):824-830. PubMed ID: 32433780
[TBL] [Abstract][Full Text] [Related]
40. The impact of underinsurance on bladder cancer diagnosis, survival, and care delivery for individuals under the age of 65 years.
Fletcher SA; Cole AP; Lu C; Marchese M; Krimphove MJ; Friedlander DF; Mossanen M; Kilbridge KL; Kibel AS; Trinh QD
Cancer; 2020 Feb; 126(3):496-505. PubMed ID: 31626340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]